Genitourinary Cancers

Genitourinary Cancers

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

In the past 5 years we have taken at least 7 steps forward for men with prostate cancer—which hopefully will turn into “one giant leap” in our attempt to convert advanced prostate cancer into a chronic disease.

This is an exciting time for physicians who care for patients with advanced prostate cancer, and more importantly a time of heightened optimism for these men and their families.

It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.

A new study shows yet another link between increasing body mass index (BMI) and the risk of several common cancers, including kidney cancer.

A large European study found that PSA screening reduces prostate cancer deaths, but that these benefits do not outweigh the harms of overtreatment.

Expression of microRNA (miR)-23b/27b cluster has been linked with increased risk for clear cell RCC disease progression, and may be a predictor of poor survival.


Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.